156 related articles for article (PubMed ID: 25801492)
1. Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma.
Yang SH; Hsiao LT; Chiou TJ; Yang CF; Yu YB; Liu CY; Gau JP; Liu JH; Chen PM; Tzeng CH
J Chin Med Assoc; 2015 Jul; 78(7):400-7. PubMed ID: 25801492
[TBL] [Abstract][Full Text] [Related]
2. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
3. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
4. Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.
Filippi AR; Piva C; Giunta F; Bellò M; Chiappella A; Caracciolo D; Zotta M; Douroukas A; Ragona R; Vitolo U; Bisi G; Ricardi U
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):311-6. PubMed ID: 23916170
[TBL] [Abstract][Full Text] [Related]
5. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
6. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
7. Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.
Lisenko K; Dingeldein G; Cremer M; Kriegsmann M; Ho AD; Rieger M; Witzens-Harig M
BMC Cancer; 2017 May; 17(1):359. PubMed ID: 28532396
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of rituximab and radiotherapy for patients with primary mediastinal large B-cell lymphoma receiving doxorubicin-containing chemotherapy.
Xu LM; Fang H; Wang WH; Jin J; Wang SL; Liu YP; Song YW; Ren H; Zhou LQ; Li YX
Leuk Lymphoma; 2013 Aug; 54(8):1684-90. PubMed ID: 23137070
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation.
Liu X; Deng T; Guo X; Guo Y; Wang L; Zhang J; Xia Z; Zhang Q; Xue K; Cao J; Shi J; Hong X
Hematology; 2017 Jun; 22(5):258-264. PubMed ID: 27884092
[TBL] [Abstract][Full Text] [Related]
10. End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
Freitas AC; Carvalho IP; Esteves S; Salgado L; Gomes da Silva M
Eur J Haematol; 2022 Feb; 108(2):118-124. PubMed ID: 34599779
[TBL] [Abstract][Full Text] [Related]
11. The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients.
Zinzani PL; Broccoli A; Casadei B; Stefoni V; Pellegrini C; Gandolfi L; Maglie R; Argnani L; Pileri S; Fanti S
Hematol Oncol; 2015 Dec; 33(4):145-50. PubMed ID: 25256959
[TBL] [Abstract][Full Text] [Related]
12. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
13. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.
Melani C; Advani R; Roschewski M; Walters KM; Chen CC; Baratto L; Ahlman MA; Miljkovic MD; Steinberg SM; Lam J; Shovlin M; Dunleavy K; Pittaluga S; Jaffe ES; Wilson WH
Haematologica; 2018 Aug; 103(8):1337-1344. PubMed ID: 29748435
[TBL] [Abstract][Full Text] [Related]
14. Primary mediastinal large B-cell lymphoma.
Bhatt VR; Mourya R; Shrestha R; Armitage JO
Cancer Treat Rev; 2015 Jun; 41(6):476-85. PubMed ID: 25913715
[TBL] [Abstract][Full Text] [Related]
15. The treatment of primary mediastinal large B-cell lymphoma: a two decades monocentric experience with 98 patients.
Broccoli A; Casadei B; Stefoni V; Pellegrini C; Quirini F; Tonialini L; Morigi A; Marangon M; Argnani L; Zinzani PL
BMC Cancer; 2017 Apr; 17(1):276. PubMed ID: 28415982
[TBL] [Abstract][Full Text] [Related]
16. The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review.
Cheah CY; Hofman MS; Seymour JF; Ritchie DS; Dickinson M; Wirth A; Prince HM; Wolf M; Januszcewicz EH; Carney DA; Herbert KE; Harrison SJ; Burbury KL; Tam CS
Leuk Lymphoma; 2015 Jan; 56(1):49-56. PubMed ID: 24724780
[TBL] [Abstract][Full Text] [Related]
17. Using PET-CT in the restaging of primitive mediastinal B-cell lymphoma (PMBCL) after chemotherapy: which criteria should we use?
Giunta F; Zotta M; Menga M; Balma M; Bellò M; Passera R; Filippi AR; Chiappella A; Ladetto M; Ricardi U; Vitolo U; Bisi G
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):214-9. PubMed ID: 25669764
[TBL] [Abstract][Full Text] [Related]
18. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.
Qiao W; Zhao J; Xing Y; Wang C; Wang T
Leuk Lymphoma; 2014 Feb; 55(2):276-82. PubMed ID: 23617323
[TBL] [Abstract][Full Text] [Related]
20. Improved survival with combined modality therapy in the modern era for primary mediastinal B-cell lymphoma.
Jackson MW; Rusthoven CG; Jones BL; Kamdar M; Rabinovitch R
Am J Hematol; 2016 May; 91(5):476-80. PubMed ID: 26852276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
